Other Events ·
Optimi Health Corp. completed and quality-released a cGMP batch of 5mg naturally derived psilocybin capsules…
OPTHOptimi Health Corp.
Optimi Health Corp. completed and quality-released a cGMP batch of 5mg naturally derived psilocybin capsules manufactured at its Princeton, British Columbia facility under a Health Canada Drug Establishment Licence. This single batch supplies both the company's recently announced Phase 2 clinical trial for major depressive disorder (MDD) in Canada and commercial customers in Australia. The Canadian trial is a multisite, open-label study of up to 200 participants receiving a single supervised dose, with patient dosing expected to conclude by the end of 2027. In Australia, the product is prescribed for treatment-resistant depression under the Therapeutic Goods Administration's Authorised Prescriber Scheme and reimbursed by various public and private payers. Optimi has supplied this psilocybin product commercially in Australia since 2025 with no reported serious adverse events. The company operates as a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products for mental health therapies.